Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia

被引：0

作者：

Zhou, Qianyi ^{[1
]}

An, Yuxin ^{[1
]}

Zhang, Xiaomei ^{[2
]}

Xiao, Xia ^{[3
]}

Bai, Xue ^{[3
]}

Liu, Pengjiang ^{[3
]}

Pu, Yedi ^{[3
]}

Meng, Juanxia ^{[3
]}

Zhu, Haibo ^{[3
]}

Lyu, Cuicui ^{[3
]}

Zhang, Huan ^{[3
]}

Zhang, Yu ^{[3
]}

Xie, Tianle ^{[3
]}

Meng, Haotian ^{[3
]}

Lyu, Hairong ^{[3
]}

机构：

[1] Tianjin Med Univ, Ctr Clin Coll 1, Tianjin, Peoples R China

[2] Tianjin First Cent Hosp, Dept Hematol, Tianjin, Peoples R China

[3] Nankai Univ, Sch Med, Tianjin, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷

基金：

中国国家自然科学基金;

关键词：

chimeric antigen receptor T (CAR-T) cell; tocilizumab; cytokine release syndrome (CRS); efficacy and safety; acute B-lymphoblastic leukemia (B-ALL); MANAGEMENT; CHILDREN; NEUROTOXICITY; IMMUNOTHERAPY; TOXICITIES; ADULTS; BLOOD;

D O I：

10.3389/fimmu.2025.1530623

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Purpose CD19 chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but cytokine release syndrome (CRS) remains a significant side effect.Methods This retrospective cohort study investigated the use of tocilizumab for managing CAR-T-related CRS in 45 R/R B-ALL patients.Results Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. Additionally, 10 patients showed decreased cytokine levels.Importantly, tocilizumab did not impair CAR-T cell expansion or efficacy, nor did it increase the incidence of adverse events.Conclusion These findings suggest that tocilizumab may be an effective and safe strategy for mitigating CAR-T-related CRS in R/R B-ALL patients, potentially improving patient outcomes and survival.

引用

页数：9

共 50 条

[31] High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
Pan, J.
Yang, J. F.
Deng, B. P.
Zhao, X. J.
Zhang, X.
Lin, Y. H.
Wu, Y. N.
Deng, Z. L.
Zhang, Y. L.
Liu, S. H.
Wu, T.
Lu, P. H.
Lu, D. P.
Chang, A. H.
Tong, C. R.
LEUKEMIA, 2017, 31 (12) : 2587 - 2593
[32] CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia
Yao, Yao
Zhou, Jin
Li, Yanting
Shi, Sensen
Yu, Lei
Wu, Depei
Wang, Ying
ANNALS OF HEMATOLOGY, 2024, : 6031 - 6033
[33] Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Zhang, Xian
Yang, Junfang
Li, Wenqian
Zhang, Gailing
Su, Yunchao
Shi, Yanze
Song, Dan
Zhang, Min
He, Jiujiang
Xu, Li
Li, Jingjing
Lu, Xinan
Li, Jianqiang
Li, Xiangqun
Xu, Zhongwei
Li, Ziyu
Lu, Peihua
BLOOD, 2020, 136
[34] Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients
Liu, Sining
Zhang, Xinyue
Dai, Haiping
Cui, Qingya
Cui, Wei
Yin, Jia
Li, Zheng
Xue, Shengli
Yang, Chunxiu
Yang, Xiao
Qiu, Huiying
Miao, Miao
Chen, Suning
Jin, Zhengming
Fu, Chengcheng
Li, Caixia
Sun, Aining
Han, Yue
Wang, Ying
Yu, Lei
Wu, Depei
Tang, Xiaowen
BLOOD, 2021, 138
[35] Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
Liu, Yadan
Liang, Bin
Liu, Yan
Wei, Guoqing
Wu, Wenjun
Yang, Luxin
Yang, Li
Huang, He
Xie, Jue
Hu, Yongxian
FRONTIERS IN PHARMACOLOGY, 2021, 12
[36] CD19-specific car-t cells for the treatment of cns chloromas in children with relapsed/refractory b-cell acute lymphoblastic leukemia
Shahid, S.
Cancio, M.
Haque, S. S.
Khakoo, Y.
McWilliams, E.
Santomasso, B. D.
Scaradavou, A.
Spitzer, B.
Wolden, S. L.
Boelens, J. J.
Curran, K. J.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 137 - 138
[37] Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
Phely, Laurent
Hensen, Luca
Faul, Christoph
Ruff, Christer Alexander
Schneider, Dina
Bethge, Wolfgang Andreas
Lengerke, Claudia
JAMA ONCOLOGY, 2024, 10 (06) : 821 - 824
[38] An owner's manual for CD19 "CAR"-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia
Laetsch, Theodore W.
Yanik, Gregory A.
Boyer, Michael W.
Rheingold, Susan R.
BLOOD REVIEWS, 2021, 50
[39] Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy
Chou, Cassie K.
Turtle, Cameron J.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (06) : 653 - 664
[40] Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Gu, Runxia
Liu, Fang
Zou, Dehui
Xu, Yingxi
Lu, Yang
Liu, Bingcheng
Liu, Wei
Chen, Xiaojuan
Liu, Kaiqi
Guo, Ye
Gong, Xiaoyuan
Lv, Rui
Chen, Xia
Zhou, Chunlin
Zhong, Mengjun
Wang, Huijun
Wei, Hui
Mi, Yingchang
Qiu, Lugui
Lv, Lulu
Wang, Min
Wang, Ying
Zhu, Xiaofan
Wang, Jianxiang
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)

← 1 2 3 4 5 →